Studies 1489 and 1490: Metabolic Complications at 3 Yr With First-line BIC/FTC/TAF, DTG/ABC/3TC, or DTG + FTC/TAF Among PWH

September 29 - October 3, 2021; Virtual
Data showed increases in BMI in all groups but no marked differences between regimens at Week 144 for treatment-emergent diabetes or hypertension or for changes in BMI.
Format: Microsoft PowerPoint (.ppt)
File Size: 513 KB
Released: October 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

From Clinical Care Options (CCO) and Dr. Jurgen K. Rockstroh and Dr. Giada Sebastiani: the risk factors of NAFLD or NASH in patients with HIV

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 7, 2021 Expired: December 6, 2022

Dr Karen Ha and Clinical Care Options (CCO): Data suggests there is a role for NNRTIs in current practice, including for patients who have experienced weight gain with INSTI-based ART.

Karen Ha, MD Released: December 6, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue